A hand-held device that would give early warning of ‘acute events’- and so avoid the hospitalisation of thousands of patients with chronic obstructive pulmonary disease (COPD) - is to go into production ahead of clinical trials. This follows an agreement between medical diagnostics company Glyconics and Spectrolytic, a leading developer of infrared (IR) spectrometers.
Glyconics Ltd
Glyconics is a company at the forefront of diagnostic innovation, using infrared spectroscopy to analyse samples for markers of disease across a wide range of conditions.
Address: St John’s Innovation Centre Cowley Road Cambridge
Post Code: CB4 0WS
Country: United Kingdom
Website: http://www.glyconics.com/
Membership Type: Professional Individual and Corporate <5
4 million people globally will end up in hospital at a cost of £14bn. Using Infrared spectroscopy, our hand-held device can diagnose and predict days before when such acute attack will happen so saving time, money and lives. Our platform can be used for a wide range of acute and chronic conditions.
Glyconics are in the Business Weekly Top 50 Cambridge companies to watch and won EU awards and UK grants.
There are no Products & Services to display
There are no events to display
There are no jobs to display
